Your browser is no longer supported. Please, upgrade your browser.
Settings
MYGN Myriad Genetics, Inc. daily Stock Chart
MYGN [NASD]
Myriad Genetics, Inc.
Index- P/E418.17 EPS (ttm)0.06 Insider Own1.40% Shs Outstand74.80M Perf Week-1.61%
Market Cap1.88B Forward P/E12.41 EPS next Y2.02 Insider Trans-18.37% Shs Float73.00M Perf Month-11.56%
Income4.60M PEG27.90 EPS next Q0.33 Inst Own- Short Float17.11% Perf Quarter1.13%
Sales851.10M P/S2.21 EPS this Y-95.70% Inst Trans- Short Ratio8.76 Perf Half Y-20.85%
Book/sh14.56 P/B1.72 EPS next Y10.80% ROA0.30% Target Price33.70 Perf Year-40.15%
Cash/sh1.83 P/C13.71 EPS next 5Y14.99% ROE0.40% 52W Range22.07 - 50.44 Perf YTD-13.69%
Dividend- P/FCF24.99 EPS past 5Y-51.50% ROI0.90% 52W High-50.01% Beta0.94
Dividend %- Quick Ratio2.70 Sales past 5Y1.80% Gross Margin76.40% 52W Low14.25% ATR2.98
Employees2400 Current Ratio3.00 Sales Q/Q11.10% Oper. Margin0.90% RSI (14)38.47 Volatility7.64% 8.73%
OptionableYes Debt/Eq0.21 EPS Q/Q-132.50% Profit Margin0.50% Rel Volume0.50 Prev Close25.09
ShortableYes LT Debt/Eq0.21 EarningsAug 13 AMC Payout0.00% Avg Volume1.43M Price25.22
Recom3.00 SMA20-28.10% SMA50-15.05% SMA200-16.13% Volume62,034 Change0.50%
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17Initiated Deutsche Bank Sell $15
Oct-10-16Downgrade Ladenburg Thalmann Neutral → Sell
Aug-10-16Reiterated Mizuho Neutral $34 → $22
Aug-22-19 08:00AM  Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. (NASDAQ: MYGN) on Behalf of Stockholders and Encourages Myriad Investors to Contact the Firm PR Newswire
07:05AM  Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention GlobeNewswire
Aug-21-19 08:13PM  MYGN Loss Alert: Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations GlobeNewswire
03:58PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:08PM  SHAREHOLDER ALERT: Investigation of Myriad Genetics Announced by Holzer & Holzer, LLC Business Wire
Aug-20-19 06:33PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Myriad Genetics, Inc. MYGN Business Wire
05:19PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Myriad Genetics, Inc. - MYGN GlobeNewswire
Aug-19-19 10:05PM  Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm PR Newswire
01:14PM  Edited Transcript of MYGN earnings conference call or presentation 13-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-17-19 01:52PM  Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More Benzinga
Aug-16-19 08:26PM  Myriad Genetics Stock Has an F.D.A. Issue Barrons.com +9.27%
04:39PM  Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc. PR Newswire
Aug-15-19 11:25AM  Myriad Genetics Limps Into Fiscal 2020 Motley Fool -9.02%
08:22AM  Myriad Genetics (NASDAQ:MYGN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Aug-14-19 06:28PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Myriad Genetics, Inc. - MYGN GlobeNewswire -42.76%
04:39PM  Why Myriad Genetics, Nordstrom, and Luckin Coffee Slumped Today Motley Fool
04:30PM  Why This Genetic-Testing Outlet Just Wiped Out Its 26% Breakout Gain Investor's Business Daily
01:19PM  Here's Why Myriad Genetics Is Getting Crushed Today Motley Fool
10:33AM  Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questions MarketWatch
09:33AM  Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up Zacks
08:55AM  Myriad Genetics Stock Craters on Weak Earnings and FDA Scrutiny Barrons.com
06:00AM  What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results Motley Fool
05:55AM  Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss TheStreet.com
Aug-13-19 09:23PM  Myriad Genetics Inc (MYGN) Q4 2019 Earnings Call Transcript Motley Fool
05:35PM  Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates Zacks
05:21PM  Will This Medical Stock Sacrifice Its Breakout On A Wide Quarterly Miss? Investor's Business Daily
04:02PM  Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results GlobeNewswire
07:46AM  Myriad Genetics Q4 Earnings Preview Benzinga
Aug-12-19 07:57AM  Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings? Zacks
06:55AM  What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings? Zacks
Aug-09-19 02:38PM  Tieton Capital Management, LLC Buys Myriad Genetics Inc, Sells Atlas Financial Holdings Inc, ... GuruFocus.com
Aug-07-19 07:05AM  Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer GlobeNewswire
Aug-06-19 04:05PM  Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019 GlobeNewswire
Aug-02-19 07:15PM  Myriad Genetics Inc (MYGN) CFO Richard Bryan Riggsbee Sold $1 million of Shares GuruFocus.com
Aug-01-19 04:28PM  Why SunPower, Myriad Genetics, and Cirrus Logic Jumped Today Motley Fool +54.46%
04:13PM  Genetic Testing: Medical Stock Ramps 50% On Insurance Coverage Investor's Business Daily
01:32PM  Here's Why Myriad Genetics Is Soaring Today Motley Fool
Jul-20-19 08:01AM  Based On Its ROE, Is Myriad Genetics, Inc. (NASDAQ:MYGN) A High Quality Stock? Simply Wall St.
Jul-09-19 09:34AM  Myriad Genetics Stock Is Falling as Enthusiasm Wanes Barrons.com
Jul-05-19 02:13PM  Heres What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Jul-02-19 02:55PM  Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues Zacks
Jun-27-19 07:28AM  Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer GlobeNewswire
Jun-25-19 07:07AM  Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer. GlobeNewswire
Jun-20-19 11:55AM  Read This Before Buying Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Simply Wall St.
Jun-19-19 07:05AM  Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan GlobeNewswire
Jun-11-19 08:00PM  Corporations Shouldn't Be Able to Patent Your DNA Bloomberg
Jun-06-19 09:31AM  Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report? Zacks
Jun-05-19 10:05AM  AngioDynamics Divests NAMIC Portfolio to Medline Industries Zacks
09:02AM  Myriad Genetics Announces Study Results Of myRisk Cancer Test Zacks
07:05AM  Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference GlobeNewswire
Jun-04-19 01:36PM  Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May Motley Fool
Jun-03-19 09:03AM  Myriad Genetics' (MYGN) POLO Study Shows Positive Results Zacks
07:05AM  Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology GlobeNewswire
Jun-02-19 09:00AM  BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) GlobeNewswire
May-30-19 07:07AM  Is Myriad Genetics, Inc.'s (NASDAQ:MYGN) CEO Salary Justified? Simply Wall St.
May-21-19 08:14AM  Why Should You Hold on to Myriad Genetics (MYGN) Stock? Zacks
May-15-19 08:15AM  Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad? Motley Fool
May-14-19 07:05AM  Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-13-19 10:28PM  Edited Transcript of MYGN earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 07:05AM  New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy GlobeNewswire
May-08-19 04:53PM  Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today Motley Fool -21.35%
09:24AM  Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript Motley Fool
07:56AM  Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up Zacks
May-07-19 07:25PM  Myriad Genetics (MYGN) Beats Q3 Earnings Estimates Zacks
06:15PM  Myriad: Fiscal 3Q Earnings Snapshot Associated Press
04:05PM  Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results GlobeNewswire
May-01-19 04:05PM  Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight® GlobeNewswire
07:05AM  Myriad Genetics to Present at Two Upcoming Healthcare Conferences GlobeNewswire
Apr-30-19 11:17AM  EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer GlobeNewswire
10:32AM  Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? Zacks
Apr-29-19 04:11PM  Heres What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Apr-23-19 04:05PM  Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019 GlobeNewswire
10:20AM  3 Medical Product Stocks Set to Beat This Earnings Season Zacks
07:05AM  Myriad to Present Multiple Womens Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting GlobeNewswire
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
Apr-17-19 03:08PM  Why Myriad Genetics, Inc. (NASDAQ:MYGN) Is A Financially Healthy Company Simply Wall St.
07:05AM  Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Councils 2019 Shatter List GlobeNewswire
Apr-09-19 07:05AM  Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test GlobeNewswire
Apr-05-19 09:33AM  Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck Zacks
Apr-04-19 08:56AM  Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake Zacks
07:05AM  Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership GlobeNewswire
Apr-02-19 07:05AM  Myriad Womens Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel Prenatal Tests GlobeNewswire
Mar-28-19 11:16AM  Myriad Genetics Gains on Innovation, New Reimbursements Zacks
Mar-21-19 07:05AM  Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting GlobeNewswire
Mar-18-19 09:03AM  Myriad's myPath Melanoma Test Awarded Medicare Coverage Zacks
Mar-14-19 08:01AM  Myriads myPath® Melanoma Test Receives Medicare Coverage GlobeNewswire +5.01%
Mar-12-19 10:11AM  Some Myriad Genetics (NASDAQ:MYGN) Shareholders Are Down 19% Simply Wall St. +6.41%
Mar-11-19 12:59PM  Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February Motley Fool
Mar-07-19 09:30AM  Why Is Myriad (MYGN) Down 0.5% Since Last Earnings Report? Zacks
07:15AM  Report: Exploring Fundamental Drivers Behind ArcelorMittal, Cohen & Steers, Myriad Genetics, Lexington Realty Trust, NorthWestern, and Chesapeake Utilities New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-06-19 07:05AM  Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine GlobeNewswire
Feb-26-19 01:10PM  Myriads BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib GlobeNewswire
Feb-22-19 07:05AM  Vectra® Study Published in the Journal Current Medical Research & Opinion GlobeNewswire
Feb-15-19 07:05AM  Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer GlobeNewswire
Feb-13-19 04:05PM  Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences GlobeNewswire
Feb-12-19 07:30AM  Detailed Research: Economic Perspectives on The Scotts Miracle-Gro, Forum Energy Technologies, Myriad Genetics, Ichor, Adesto Technologies, and Viad What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-11-19 07:05AM  Myriad Announces Prequel Prenatal Screen with Expanded Aneuploidy Analysis for all 23 Chromosome Pairs GlobeNewswire
Feb-08-19 10:55AM  Edited Transcript of MYGN earnings conference call or presentation 5-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
07:05AM  Myriad to Present New Data for Its Expanded Carrier and Noninvasive Prenatal Screens at the 2019 Society for Maternal-Fetal Medicine Annual Meeting GlobeNewswire
Feb-06-19 09:07AM  Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates Zacks
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Capone Mark ChristopherPresident & C.E.O.Aug 01Option Exercise26.38137,0003,614,330511,505Aug 02 05:45 PM
King Gary A.Exec. VP International OpsAug 01Option Exercise23.7360,0001,423,900164,871Aug 02 04:44 PM
Tobin BernardPresident Crescendo BioScienceAug 01Sale40.0011,712468,480146,040Aug 02 04:40 PM
Riggsbee Richard BryanChief Financial OfficerAug 01Sale41.5025,0001,037,575120,566Aug 02 04:32 PM
Capone Mark ChristopherPresident & C.E.O.Aug 01Sale44.00137,0006,028,000440,833Aug 02 05:45 PM
King Gary A.Exec. VP International OpsAug 01Sale43.4960,0002,609,329134,871Aug 02 04:44 PM
McDade Ralph LPresident Myriad RBM, Inc.Mar 12Sale31.001,97561,225122,604Mar 12 05:56 PM